| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JACC.2018.11.067 |
| P698 | PubMed publication ID | 31023428 |
| P50 | author | Daniel S Berman | Q89697826 |
| P2093 | author name string | William S Weintraub | |
| Koon K Teo | |||
| William E Boden | |||
| G B John Mancini | |||
| John A Spertus | |||
| David J Maron | |||
| Pamela M Hartigan | |||
| William J Kostuk | |||
| COURAGE Trial Research Group | |||
| P2860 | cites work | Influence of Lifestyle on Incident Cardiovascular Disease and Mortality in Patients With Diabetes Mellitus | Q89180180 |
| Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q90959912 | ||
| Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424 | Q28219178 | ||
| Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). | Q30687917 | ||
| Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus | Q33590908 | ||
| Participation in cardiac rehabilitation, readmissions, and death after acute myocardial infarction. | Q33671225 | ||
| Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS Study (REasons for Geographic And Racial Differences in Stroke). | Q34364029 | ||
| Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes | Q34540403 | ||
| Optimal medical therapy with or without PCI for stable coronary disease | Q34612445 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial. | Q35999237 | ||
| Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
| Is glucose control important for prevention of cardiovascular disease in diabetes? | Q37577137 | ||
| Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| A Systematic Review of the Prevalence and Outcomes of Ideal Cardiovascular Health in US and Non-US Populations | Q38796862 | ||
| Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Q40287836 | ||
| Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease | Q40331861 | ||
| Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. | Q40619323 | ||
| Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial | Q43118512 | ||
| Participation in cardiac rehabilitation and survival after coronary artery bypass graft surgery: a community-based study | Q44120126 | ||
| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes | Q44295713 | ||
| Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
| The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention | Q47138150 | ||
| Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients | Q47432715 | ||
| Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. | Q53098804 | ||
| Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial | Q58607321 | ||
| Healthy Weight and Obesity Prevention | Q60177525 | ||
| Risk Factor Control for Coronary Artery Disease Secondary Prevention in Large Randomized Trials | Q61069719 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report | Q63694274 | ||
| P433 | issue | 16 | |
| P921 | main subject | glycated hemoglobin | Q311213 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 2049-2058 | |
| P577 | publication date | 2019-04-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes | |
| P478 | volume | 73 |
| Q94595415 | Authors' Reply to the Letter by Shoar et al. on "Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo" |
| Q93089423 | Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies |
| Q96109868 | In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events |
| Q91519294 | Lifestyle Interventions in Diabetes and Coronary Disease: A Timely Reminder |
| Q97556760 | Limited Agreement between Classifications of Diabetes and Prediabetes Resulting from the OGTT, Hemoglobin A1c, and Fasting Glucose Tests in 7412 U.S. Adults |
| Q92863498 | Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease |
| Q92386348 | The role of coronary artery bypass surgery versus percutaneous intervention in patients with diabetes and coronary artery disease |
| Q89580470 | Time to Rethink Reducing Cardiovascular Risk: Are We Ready? |
| Q90596667 | Weighing Coronary Revascularization Options in Patients With Type 2 Diabetes Mellitus |
Search more.